E2814
Sponsors
Washington University School Of Medicine, Washington University School of Medicine, Eisai Inc.
Conditions
Alzheimer DiseaseAlzheimer's DiseaseAlzheimers DiseaseAlzheimers Disease, FamilialDementiaDominantly Inherited Alzheimer Disease (DIAD)Healthy Volunteers
Phase 1
A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants
CompletedNCT04231513
Start: 2019-12-16End: 2023-03-09Updated: 2023-04-06
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
CompletedNCT04971733
Start: 2021-06-28End: 2024-05-24Updated: 2025-06-10
Phase 2
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Active, not recruitingNCT01760005
Start: 2012-12-01End: 2028-07-01Target: 490Updated: 2026-02-13
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Active, not recruitingNCT05269394
Start: 2021-12-22End: 2028-07-01Updated: 2026-02-13
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer’s Disease (DIAD)
Active, not recruitingCTIS2024-515198-91-00
Start: 2022-12-20Target: 24Updated: 2025-07-04
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Active, not recruitingNCT06602258
Start: 2024-09-30End: 2027-08-18Updated: 2026-02-11